Serum thymosin β4 demonstrated superior diagnostic accuracy (AUROC 0.908) compared to the standard marker AFP (AUROC 0.712) for hepatocellular carcinoma, and independently predicted shorter survival.
AUROC 0.908 vs 0.712 for AFPThymosin β4 outperformed the standard liver cancer marker AFP by a substantial margin in diagnostic accuracy across 540 patients, including those with cirrhosis and hepatitis who are hardest to distinguish from early cancer.
What the researchers found
Thymosin β4 was identified in serum by MALDI-TOF mass spectrometry and validated in 540 subjects (274 HCC, 119 cirrhosis, 89 hepatitis, 58 healthy). Serum Tβ4 was significantly elevated in HCC patients. Diagnostic performance: AUROC for Tβ4 was 0.908 (95% CI 0.880-0.935) versus AFP at 0.712 (95% CI 0.662-0.762), with optimal cutoff at 1063.6 ng/mL. Elevated Tβ4 was significantly associated with tumor size (p=0.016) and vascular invasion (p=0.005). Survival was significantly shorter in Tβ4-positive patients (p<0.001). Cox regression confirmed Tβ4 as an independent prognostic factor.
Why it matters
Liver cancer is the third leading cause of cancer death worldwide, and late diagnosis is a major reason for poor outcomes. AFP, the current standard blood marker, misses about 30-40% of liver cancers. A blood test with 91% diagnostic accuracy (vs. 71% for AFP) could catch significantly more cancers early, when treatment is most effective. Thymosin β4's additional prognostic value adds to its clinical utility.
How the study worked
540 subjects enrolled across four groups: HCC (274), liver cirrhosis (119), hepatitis (89), and healthy volunteers (58). MALDI-TOF mass spectrometry was used for initial biomarker discovery from serum. Tβ4 expression was validated in HCC cell lines and tissue samples. Serum levels were measured and diagnostic performance evaluated by ROC analysis with comparison to AFP. Clinical correlations with tumor characteristics and survival were assessed. Cox regression identified independent prognostic factors.
What this study cannot tell us
Single-center study, which limits generalizability. The biomarker discovery and validation were performed in the same cohort — external validation in independent populations is needed. The study was cross-sectional, so the utility of Tβ4 for longitudinal surveillance (serial testing over time) was not assessed. The mechanism by which Tβ4 is elevated in serum (tumor secretion vs. tissue destruction) was not fully characterized. Comparison was made to AFP alone, not to other emerging HCC markers like PIVKA-II.
How to read the evidence
This is a well-powered single-center study with a substantial sample size (540 subjects) including appropriate control groups. The combination of biomarker discovery, expression validation, and clinical outcome analysis is thorough. However, external validation and prospective surveillance studies are needed before clinical adoption.
When this study was published
Published in 2023, this study reflects ongoing efforts to improve liver cancer early detection. Thymosin β4 as a biomarker has not yet entered routine clinical practice but represents a promising candidate.
The bigger picture
Thymosin β4 has been studied extensively for its roles in wound healing, tissue repair, and inflammation. This study adds cancer diagnosis to its clinical potential. The finding that a peptide involved in cell motility is elevated in an aggressive cancer makes biological sense — Tβ4 promotes cell migration, which is a key feature of cancer invasion and metastasis. This connects peptide biology directly to cancer detection.
Questions still open
- Will thymosin β4's diagnostic superiority over AFP be confirmed in independent multi-center validation studies?
- Could combining thymosin β4 with AFP or other markers create an even more accurate diagnostic panel?
- Is serum thymosin β4 elevated in other cancers that involve high cell motility and invasion?
Common questions
What is thymosin β4 and why could it be a liver cancer marker?
Could thymosin β4 replace AFP for liver cancer screening?
Read the original research
Thymosin β4, a potential marker of malignancy and prognosis in hepatocellular carcinoma.
Scandinavian journal of gastroenterology, 58(4), 380-391
Citation
Wang, Wen-Chao; Zhang, Xiao-Feng; Tang, Er-Jiang; Li, A-Jian; Chen, Lei; Wang, Jia-Qi; Ma, Jun-Yong; Zhang, Xiao-Feng; Sun, Bin. (2023). Thymosin β4, a potential marker of malignancy and prognosis in hepatocellular carcinoma.. Scandinavian journal of gastroenterology, 58(4), 380-391. https://doi.org/10.1080/00365521.2022.2136012